###### Strengths and limitations of this study

-   This will be the first nationwide population-based study in Japan to investigate the impact of a cancer diagnosis on subsequent death by suicide, other externally caused injuries and cardiovascular events.

-   Our study will cover virtually all cancer incidence and subsequent fatal outcomes in Japan.

-   Our study will not be able to control for potential confounding factors for cancer, suicide and cardiovascular events, such as smoking history and alcohol use, sociodemographic status and pre-existing medical and psychiatric conditions.

Introduction {#s1}
============

In Japan, it is estimated that \~1 million people have been newly diagnosed with cancer annually in recent years, and about 1 in 2 Japanese will receive a cancer diagnosis during their lifetime.[@R1]

Receiving a cancer diagnosis and undergoing diagnostic workup leading to a definite cancer diagnosis are highly stressful experiences for cancer patients, and a high prevalence of psychiatric symptoms and disorders has been observed around the time of a cancer diagnosis.[@R2] A number of population-based studies have consistently demonstrated that patients with cancer are at increased risk for suicide,[@R4] especially in the weeks after their cancer diagnosis.[@R16] A high incidence of other externally caused injuries (ECIs), including accidental death and death due to events of undetermined intent, has also been reported among cancer patients.[@R20] Some suicide deaths may be misclassified as other ECIs,[@R23] and physical, psychological and social impairment due to cancer itself or adverse effects of cancer treatment could increase the risk of accidental death.[@R25]

Furthermore, a few population-based studies have demonstrated that the period immediately after a cancer diagnosis is related to elevated mortality from cardiovascular causes among patients with prostate cancer[@R26] and those with other cancer types as well.[@R17] Acute psychological stressors, such as earthquakes, war and the death of a loved one, are known to trigger cardiovascular events.[@R28] Acute emotional distress induced by a cancer diagnosis may also affect cardiovascular functioning and cause critical outcomes beyond the influence of cancer itself or cancer treatment. Possible mechanisms linking acute psychological stressors to cardiovascular events include pathophysiological pathways that have the potential to cause rupture of vulnerable plaque, thrombosis formation or fatal arrhythmias (eg, increased sympathetic tone, blood pressure, shear stress and blood viscosity; endothelial dysfunction; and hypercoagulability), and health-impairing behaviours related to emotional distress.[@R28]

Suicide risk among persons with cancer has been suggested to differ between different ethnic and cultural groups.[@R32] Two previous studies have reported risk of suicide among Japanese patients with cancer compared with the general population.[@R22] The first, a single-institution study demonstrated that suicide risk among patients newly diagnosed with cancer was significantly elevated within the first year after a diagnosis.[@R33] The second, a population-based prospective study investigating Japanese residents including over 10 000 cancer patients, showed that risk of death by suicide and other ECIs was about 24 and 19 times higher, respectively, among those with cancer within the first year after a cancer diagnosis than among those without cancer.[@R22] There has been no nationwide study examining the risk of suicide among cancer patients in Japan, and cardiovascular mortality risk following a cancer diagnosis has not been investigated in countries other than Sweden and the USA. As Japan is ageing faster than any other country in the world and the number of patients with newly diagnosed cancer is expected to keep increasing,[@R34] the impact of a cancer diagnosis on subsequent stress-related outcomes is a serious public health issue. It is necessary to identify vulnerable patients and the window of maximum risk in order to implement appropriate supportive and preventive intervention.

The Act on Promotion of Cancer Registries was enacted in Japan in 2013 and the National Cancer Registry (NCR) in Japan was launched on 1 January 2016.[@R35] According to the Act, hospitals in Japan have a legal duty to report all targeted cancer cases (ie, intraepithelial and malignant tumours corresponding to a behavioural code of 2 or 3 in the International Classification of Diseases for Oncology, Third Edition; benign and uncertain whether benign or malignant central nervous system (CNS) neoplasms and gastrointestinal stromal tumours; and some types of ovarian borderline malignant tumours) to the NCR. The NCR has enabled hospitals to calculate accurate cancer incidences and survival rates, and it is expected that the NCR database will contribute to planning and assessment of evidence-based cancer control policies and promote research in such areas as evaluation of cancer care quality and follow-up surveys in nationwide cohort studies. The first NCR data will become available for research purposes in 2019.

Using data from the NCR, we will conduct the first nationwide population-based study in Japan to characterise the incidence of death by suicide, ECIs and cardiovascular disease among patients with a cancer diagnosis compared with the general population in Japan. We will also aim to identify higher-risk patients and time periods that may require more attention. We hypothesise that the risk of suicide, other ECIs and cardiovascular death is significantly higher within the first year after a cancer diagnosis and that the period soon after a cancer diagnosis is associated with the greatest risk.

Methods {#s2}
=======

Data sources {#s2a}
------------

Cancer patients will be identified from the NCR database in Japan. The NCR covers the total population in Japan, and hospitals are required to report all targeted cancer cases newly diagnosed in their institutions from 1 January 2016 onwards, irrespective of patient nationality. The NCR system in Japan is described in [figure 1](#F1){ref-type="fig"}. Incidence data from cancer care hospitals are submitted to prefectual governors and prefectural governors review and match record in their prefecture and enter the data in the NCR database in the Ministry of Health, Labour and Welfare (MHLW) (National Cancer Center (NCC)). The MHLW/NCC matches the cancer registry data interprefectually and information from death certificate on cancer disease is matched with the incidence data in the NCR. The NCC follows up cancer patients in the NCR database by linking to national death certificate data and registers death information in the NCR. The unit of registration is tumour, duplications of the same cancer case are corrected and each cancer is registered separately for cases in which a patient is judged to have multiple primary cancers based on pathology. Data aggregation is based on name, birth date and address of patients. The data collection deadline for each year's cases is the end of the following year, and the data will become available for research purposes the year after that. Data quality of the NCR for year 2016 cases has been reported to be very high: the proportion of death certificate notification was 4.5%, the proportion of death certificate only was 3.2%, the mortality incidence ratio was 0.37, and the morphological verification proportion was 85.4%.[@R37]

![The National Cancer Registry (NCR) system in Japan. Reporting of newly diagnosed cancer cases from 1 January 2016 onwards has become a legislative duty of hospitals in Japan. Information collected in each prefecture must be registered in the NCR database and the National Cancer Center (NCC) follows up patients in the NCR by linking to mortality data based on national death certificate files. MHLW, Ministry of Health, Labour and Welfare.](bmjopen-2019-030681f01){#F1}

The standard items submitted to the NCR by cancer care hospitals are presented in [table 1](#T1){ref-type="table"}. The date of cancer diagnosis is defined as the date of the most definitive diagnostic test before initiation of treatment and diagnostic tests are arranged hierarchically by levels of definitiveness as follows: histopathological testing of primary tumour, histopathological testing of metastatic tumour, cytology, certain kind of tumour-specific markers, other clinical testing and clinical diagnosis.[@R38] Information such as race, educational status, marital status, income, insurance status and comorbidity is not registered in the NCR database.

###### 

Items submitted to the National Cancer Registry in Japan by cancer care hospitals

  ------------------------------------------ ------------------------------------------
  1\. Name of hospital                       14\. Date of diagnosis
  2\. Patient's identification (ID) number   15\. Circumstance of cancer detection
  3\. Name (Hiragana)                        16\. Extension of disease (clinical)
  4\. Name (Kanji)                           17\. Extension of disease (pathological)
  5\. Sex                                    18\. Surgery of primary site
  6\. Birth date                             19\. Laparo/thoracoscopic surgery
  7\. Address of patients                    20\. Endoscopic surgery
  8\. Laterality                             21\. Result of surgery
  9\. Diagnosis (primary site)               22\. Radiation therapy
  10\. Diagnosis (morphology)                23\. Chemotherapy
  11\. Diagnosis facility                    24\. Endocrinotherapy
  12\. Treatment facility                    25\. Other treatment
  13\. Basis of diagnosis                    26\. Date of death
  ------------------------------------------ ------------------------------------------

Details of the NCR system have been described previously.[@R35]

Study population and inclusion criteria {#s2b}
---------------------------------------

Our study cohort will consist of all cancer cases diagnosed in Japan between 1 January 2016 and 31 December 2016 and registered in the NCR and they will be followed until 31 December 2018. We will exclude cancer cases that are diagnosed incidentally at autopsy, reported only on a death certificate or missing a diagnosis date. For individuals with multiple cancers, the start of the at-risk period will be defined as the date of the most recent cancer diagnosis. A total of 995 132 malignant cancer cases (defined by C00--C96 according to International Classification of Diseases, 10th Edition (ICD-10)) were diagnosed in Japan in 2016,[@R37] and about 1 million cancer patients will be included in our study.

Study variables {#s2c}
---------------

We will identify cancer patients who died by suicide, ECIs and cardiovascular causes based on underlying cause of death according to ICD-10 registered in the NCR database. Outcomes will be classified as follows: suicide (X60--X84 and Y87.0), other ECIs (V01--X59 and Y10--Y34) and cardiovascular diseases (I00--I99). Cardiovascular death will be further subcategorised as myocardial infarction (I21--I24), other disease of the heart (I10--I13, I71 and I72), embolism or thrombosis (I26, I74, I80.1, I81, I82 and I85.0), stroke (I60--I64), haemorrhagic stroke (I60--I62), ischaemic stroke (I63) and others. Quality of cause of death information in Japan has been reported to be high.[@R39] Other information we will obtain from the NCR includes sex, age at diagnosis, prefecture of residence at diagnosis, presence/absence of multiple primary tumours, primary site of tumour according to ICD-10 codes, basis of diagnosis, date of diagnosis, extension of tumour, presence/absence of each treatment, presence/absence of definitive surgery of the primary site, hospital region, survival status and survival time.

Statistical analysis {#s2d}
--------------------

Person-years at risk will be computed from the date of a cancer diagnosis to the date of death, or December 31 2018, whichever comes first. Standardised mortality ratios (SMRs) will be calculated as the observed numbers of targeted events (ie, suicide, other ECIs or cardiovascular death) among cancer patients divided by the expected numbers of events in the general population. Excess absolute risks (EARs) will be calculated by subtracting the expected numbers of events from the observed numbers of events; the difference will be then divided by person-years of cancer patients, and the number of events in excess will be expressed per 10 000 person-years. The expected numbers of events will be obtained by multiplying the number of person-years at risk, stratified by sex, age group (0--4, 5--9, ..., 80--84, ≥85 years), prefecture and calendar year, by mortality rates from targeted events in each year in the general population in Japan in each corresponding stratum. We will calculate mortality rates by sex, age and prefecture in each year in the general population by dividing the numbers of death from each event occurring in Japan (based on datasets from Vital Statics Japan, provided by the MHLW) by the estimated total population in Japan based on population estimates.[@R40] The numbers of death by each targeted event in the general population will be calculated by using the same definition according to ICD-10 codes as those used in the cancer patients. We will calculate 95% CIs of SMRs and EARs by assuming that the observed numbers of events follow a Poisson distribution.

SMRs and EARs will be calculated separately in relation to a number of factors: sex, age at diagnosis, time since cancer diagnosis, prefecture of residence at diagnosis, primary tumour site, behavioural code of tumour, extension of tumour, whether definitive surgery of the primary site was performed, and presence/absence of multiple tumour. Age at diagnosis will be stratified into the following groups: 0--39, 40--49, 50--59, 60--69, 70--79 and ≥80 years. Time after a cancer diagnosis will be divided into 0--2, 3--5, 6--11 and ≥12 months for suicide and other ECIs. Risk of suicide and other ECIs during the first week after diagnosis will be also separately calculated. For cardiovascular death, we will investigate \<1 week, 1 week to \<1 month, 1--5 months, 6--11 months and ≥12 months. Primary tumour site will be based on the classifications used in the Monitoring of Cancer Incidence in Japan project ([table 2](#T2){ref-type="table"}).[@R41] The extension of tumour will be classified into localised (confined to the original organ), regional (spread to regional lymph nodes and/or adjacent tissue), metastatic (metastasised to distant organ) and unknown. Stroke will be excluded from cardiovascular mortality in the analysis of CNS tumours, and CNS tumours will be excluded from 'any cancer' in the analysis of death from cardiovascular causes.[@R17] Cases of hematological disease will be excluded in the analysis of presence/absence of definitive surgery. Likelihood ratio tests based on Poisson regression models will be conducted to test for heterogeneity. All p value will be two-sided tests and be considered to be statistically significant at a p value of \<0.05. We will also perform multivariable regression analysis based on Poisson regression models to adjust for following factors: sex, age at a cancer diagnosis, primary tumour site, extension of tumour, presence/absence of multiple tumours and follow-up period. All factors will be included in the multivariable regression model with no interaction terms. We will also test for the heterogeneity from the multivariable models.

###### 

Primary tumour site according to International Classification of Diseases, 10th Edition code used in the Monitoring of Cancer Incidence in Japan project[@R41]

  --------------------------------------------------------- ------------------------------------------------------------
  Any cancer (C00--C96, D00--D09)                           Breast (C50, D05)
  Oral cavity and pharynx (C00--C14)                        Uterus (C53--C55, D06)
  Oesophagus (C15, D001)                                    Cervix uteri (C53, D06)
  Stomach (C16)                                             Corpus uteri (C54)
  Colon and rectum (C18--C20, D010--D012)                   Ovary (C56)
  Colon (C18 and D010)                                      Prostate (C61)
  Rectum (C19--C20, D011--D012)                             Bladder (C67, D090)
  Liver and intrahepatic bile ducts (C22)                   Kidney and urinary organs (except bladder) (C64--C66, C68)
  Gallbladder and other parts of biliary tract (C23--C24)   Brain and other parts of central nervous system (C70--C72)
  Pancreas (C25)                                            Thyroid (C73)
  Larynx (C32)                                              Malignant lymphoma (C81--C85, C96)
  Lung and bronchus (C33--C34, D021--D022)                  Multiple myeloma (C88, C90)
  Skin (C43--C44, D030--D049)                               Leukaemia (C91--C95)
  --------------------------------------------------------- ------------------------------------------------------------

In order to explore the factors affecting their choice of suicide method by cancer patients, we will describe distribution of characteristics of patients and tumours (eg, sex, age at diagnosis, extension of tumour and time since diagnosis) by common suicide methods in Japan (eg, poisoning (X60--X69), hanging (X70) and jumping from heights (X80)).

We will also divide cancer patients who die during the observation period into two groups according to the main cause of death: (1) suicide, other ECIs and cardiovascular diseases and (2) others. Characteristics of patients and tumours will be compared between two groups.

All analyses will be performed using SPSS Statistics for Windows V.25.0.

Discussion {#s3}
==========

This will be the first nationwide study in Japan to investigate the impact of a cancer diagnosis on subsequent death by suicide, other ECIs and cardiovascular events. The main strength of this study is that it will cover virtually all cancer incidence and subsequent fatal outcomes in Japan using information registered in the NCR. SMRs and EARs of stress-related outcomes after a cancer diagnosis will help to identify higher-risk patients and time periods, and will provide useful evidence for considering the priority of preventive strategies.

Several limitations inherent in this study should be acknowledged. First, our study will not be able to control for potential confounding factors for cancer, suicide and cardiovascular events, such as smoking history and alcohol use, sociodemographic status and pre-existing medical and psychiatric conditions. These data are not collected in the NCR and we cannot link anonymous cancer registry information to other medical and socioeconomic databases. Second, our study will explore mortality outcomes alone and we cannot capture nonfatal outcomes, such as suicidal ideation, attempted suicide and non-lethal cardiovascular events. Our findings will represent only a small portion of the psychological burden associated with a cancer diagnosis. Third, some deaths classified as other ECIs may be misclassification of deaths due to suicide,[@R23] and assuming that more under-reporting of suicide occurs in cancer patients than in the general population, risk of suicide among cancer patients in our study will be potentially underestimated. Fourth, in the analysis of presence/absence of definitive surgery of the primary tumour, the result should be interpreted with caution because only patients who did not die by targeted outcomes and survived until surgery could undergo surgery. Finally, if death ascertainment in the NCR system is incomplete, risk of deaths by targeted causes among cancer patients can be underestimated.
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